• Customer Login
  • Search
KindredBio
  • About
    • Background
    • Our Story
    • KindredBio Leadership
    • Board of Directors
  • Pipeline
    • Canine Pipeline
    • Clinical Trials
  • Products
    • Zimeta™ (dipyrone injection)
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Education
    • Continuing Education
    • KINections
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Stock Information
    • Financial Information
    • Investor Resources
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Menu

Test PI PDF Embed

You are here: Home / Test PI PDF Embed
Mirataz_Full_PI

News

  • Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK StudyApril 20, 2021 - 4:05 pm
  • Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial ResultsMarch 16, 2021 - 4:05 pm
  • Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial ResultsMarch 8, 2021 - 8:40 am

Events

  • Event: Kindred Biosciences to Announce Fourth Quarter and Full Year 2020 Financial ResultsMarch 8, 2021 - 8:48 am
  • Event: Kindred Biosciences to Present at the H.C. Wainwright Global Life Sciences ConferenceMarch 2, 2021 - 8:45 am
  • Event: Kindred Biosciences to Present at the Barclays Global Healthcare ConferenceMarch 2, 2021 - 8:43 am
$4.71 Stock is Up 0.06 (1.29%)
KIN (Common Stock)
Previous Close Volume
$4.65 523,071
Intraday High Intraday Low
$4.76 $4.48
52 Week High 52 Week Low
$6.00 $3.20
Exchange: NASDAQ CM
Contact Us | Careers | Privacy Policy | Website Terms of Use | Forward Looking Statements
© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010
Scroll to top